患有左心室缩功能障碍的患者血中低卡诺辛酶-1活性:对心力衰竭中卡诺辛治疗的影响
I-Chau Liang1, Ettore Gilardoni1, Islam A Berdaweel1,2
1Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
International journal of molecular sciences
|March 27, 2025
概括
血肉氨酶-1 (CN1) 活性,而不是含量,在心力衰竭患者中较低. 这表明CN1活性是独立于表达的调节,影响心力衰竭的二治疗.
科学领域:
- 生物化学 生物化学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 像卡诺辛这样的基二酸具有治疗潜力,但被卡诺辛酶-1 (CN1) 降解.
- 以前的研究表明,口服卡诺辛对心力衰竭 (HF) 的心脏代谢参数有好处.
- HF对CN1活动的影响尚不清楚.
研究的目的:
- 调查左心室 (LV) 缩功能障碍患者的血CN1含量和肉氨酸降解率 (CDR) 是否不同.
- 探索CN1活动与LV缩功能障碍的严重程度之间的关系.
主要方法:
- 从138名心脏手术患者的手术前血中测量了CN1含量和CDR.
- 分析了血CDR分布,并将其与包括LV喷射分数 (EF) 在内的临床因素相关联.
- 使用后勤回归来评估CDR,CN1特异性活性和LV缩功能障碍严重程度之间的关联.
主要成果:
- 血CDR显示了准双模分布 (高与低活性).
- 低CDR活性与女性性别,糖尿病和LV缩功能障碍有关.
- 与正常EF (≥50%) 患者相比,中度和重度LV系统功能障碍 (EF <50%) 的患者的CDR和CN1特异性活性显着较低.
- 在EF组中,CN1含量没有显著差异.
结论:
- 血CN1活性,但不一定是其含量,降低了患有乳房缩功能受损的患者.
- 似乎CN1活动受到超出单纯表达水平的因素的调节.
- 这些发现对开发基于肉的治疗方法产生影响,用于治疗心脏代谢障碍,如高血压.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
01:26Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
39
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
39
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299